“Half the Price of Mounjaro”: South Korea’s First Homegrown Obesity Drug Epe Enters the Market
The first domestically developed obesity medication is entering South Korea’s weight-loss market, long dominated by foreign pharmaceuticals such as...
Search results for "drug treatment"
Study Provides Real-World Guidance for Treating Isoniazid-Resistant Tuberculosis
A real-world clinical study evaluating a World Health Organization -recommended treatment for drug-resistant tuberculosis found no statistically...
Lexraza Developer and Lilly Obesity Chief to Headline Global Clinical Trial Summit in Seoul
What will it take to build on the success of Lexraza, South Korea’s landmark lung cancer drug, and propel it into the...
Hanmi’s ‘Epe’ Wins MFDS Approval, Becoming South Korea’s First Homegrown GLP-1 Obesity Drug
A domestically developed therapy has entered South Korea’s obesity treatment market, long dominated by imported...
Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports
GLP-1 (glucagon-like peptide-1) class medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, are...
Same Arthritis Drug, Different Results: Why Treatment Nonresponse Is Not Your Fault
If two patients take the exact same medication, why does one recover while the other sees little to no improvement.
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide
JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s...
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C...
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival
Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...
Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy
CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical...